Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Argos Therapeutics
About
Argos Therapeutics develops immunotherapy treatments for cancers, infectious and autoimmune diseases, and transplantation rejection.
- 101 - 250
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $25M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 1997
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 15, 2016 | Post-IPO Equity | $60M | 1 | — | — | Detail |
| Sep 30, 2014 | Post-IPO Debt | $25M | 1 | — | — | Detail |
| Nov 20, 2013 | Series E | $17.50M | 1 |
|
— | Detail |
| Aug 26, 2013 | Series E | $42.50M | 2 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series E |
Inbio Ventures
|
— | Post-IPO Equity |
Horizon Technology Finance
|
— | Post-IPO Debt |
Aurora Private Equity
|
— | Series E |
